EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prognostic Factors in Pleural Mesothelioma Patients Receiving First-Line Chemotherapy: Establishing the PLECH Baseline Risk Score

Alberto Guijosa, Luis Antonio Cabrera-Miranda, Ana Pamela Gómez-García, Rogelio Trejo Rosales, Wendy Muñoz-Montaño, Diana Flores, Nancy Reynoso-Noverón, Oscar Arrieta

Oncology · 2025

DOI: 10.1159/000543637 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2025. Verfasst von Alberto Guijosa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Oncology Unit, National Cancer Institute Mexico (INCan), Mexico City, Mexico. Hauptthemen laut MEDLINE: Pleural Neoplasms, Mesothelioma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pleural mesothelioma (PM) is a rare and aggressive cancer where prognostic assessment is crucial. Traditional prognostic scores such as the European Organization for Research and Treatment of Cancer (EORTC) and the Cancer and Leukemia Group B (CALGB) have limitations, particularly in reflecting contemporary treatments and demographic diversities, while more recent scores often include novel biomarkers, not widely available and validated. Our goal was to create an effective prognostic score for PM using readily available baseline data.

Methods

A retrospective cohort study at two Mexican cancer centers included patients with unresectable PM treated with the first-line chemotherapy from 2010 to 2023. Baseline variables’ associations with overall survival (OS) and progression-free survival (PFS) were analyzed. Prognostic variables from univariate and multivariate analyses formed a baseline risk score. The score’s OS prediction was compared to standard CALGB and EORTC scores using ROC curves and Kaplan-Meier analysis.

Results

Among 262 patients (69.1% male, 80.5% epithelioid histology), we developed a 0–7 point PLECH score based on five variables: platelet count (P: +2), high LDH (L: +1), ECOG ≥2 (E: +1), chest pain at diagnosis (C: +2), and non-epithelioid histology (H: +1). The score had an area under the curve of 0.70 for predicting 1-year OS, outperforming CALGB (0.60) and EORTC (0.57) scores, with an optimal cut-off of 2.5 (sensitivity 75%, specificity 55%). High scores (≥3) indicated worse OS (12.3 vs. 20.1 months; p < 0.001) and PFS (6.4 vs. 11.3 months; p < 0.001).

Conclusion

The PLECH score, developed from a substantial Latin-American cohort, is a simple and effective prognostic tool for PM patients, outperforming traditional scores. It identifies a high-risk group potentially better suited to alternative treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pleural NeoplasmsMesotheliomaAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedRetrospective StudiesPrognosisAgedAdultMesothelioma, MalignantAged, 80 and overRisk AssessmentProgression-Free SurvivalKaplan-Meier Estimate

Stichwörter der Autor:innen

ChemotherapyLatin AmericaMesotheliomaPrognosisSurvival

Autor:innen und Institutionen

  • Thoracic Oncology Unit, National Cancer Institute Mexico (INCan), Mexico City, Mexico.
  • Oncology Hospital, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
  • Medical Oncology, Fundación Clínica Médica Sur, Mexico City, Mexico.
  • Epidemiology Unit, National Cancer Institute Mexico (INCan), Mexico City, Mexico.
  • Thoracic Oncology Unit, National Cancer Institute Mexico (INCan), Mexico City, Mexico, oscararrietaincan@gmail.com.
  • Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico, oscararrietaincan@gmail.com.

Zitieren

APA

Guijosa, A., Cabrera-Miranda, L. A., Gómez-García, A. P., Trejo Rosales, R., Muñoz-Montaño, W., Flores, D., Reynoso-Noverón, N., & Arrieta, O. (2025). Prognostic Factors in Pleural Mesothelioma Patients Receiving First-Line Chemotherapy: Establishing the PLECH Baseline Risk Score. Oncology. https://doi.org/10.1159/000543637

Vancouver

Guijosa A, Cabrera-Miranda LA, Gómez-García AP, Trejo Rosales R, Muñoz-Montaño W, Flores D, et al. Prognostic Factors in Pleural Mesothelioma Patients Receiving First-Line Chemotherapy: Establishing the PLECH Baseline Risk Score. Oncology. 2025. doi:10.1159/000543637

BibTeX
@article{Guijosa2025,
  author = {Guijosa, Alberto and Cabrera-Miranda, Luis Antonio and Gómez-García, Ana Pamela and Trejo Rosales, Rogelio and Muñoz-Montaño, Wendy and Flores, Diana and Reynoso-Noverón, Nancy and Arrieta, Oscar},
  title = {Prognostic Factors in Pleural Mesothelioma Patients Receiving First-Line Chemotherapy: Establishing the PLECH Baseline Risk Score},
  journal = {Oncology},
  year = {2025},
  doi = {10.1159/000543637}
}
Kostenlos starten →